The Clinical Research Transformation: Future Outlook 2026 conference opened today, Monday, in Riyadh. Organized by King ...
Please provide your email address to receive an email when new articles are posted on . Attendees will get insights into evaluation and treatment of complications that arise from stem cell ...
The 2023 Fall Clinical Dermatology conference featured research on treatments for alopecia areata, acne, psoriasis, atopic dermatitis, and vitiligo. The Fall Clinical Dermatology conference presented ...
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg ...
The MarketWatch News Department was not involved in the creation of this content. Dubai, United Arab Emirates--(Newsfile Corp. - October 31, 2025) - International Modern Hospital (IMH) successfully ...
MDA Legacy Award for Achievement in Clinical Research to honor Michio Hirano, MD, Columbia University Irving Medical Center ...
NEW YORK, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Today, Questex’s Patients as Partners® in Clinical Research, the first conference to put patients at the same level as R&D executives in a national event, ...
Please provide your email address to receive an email when new articles are posted on . Following a successful meeting in 2022, the Heart in Diabetes Conference is looking forward to hosting its ...
Cabaletta Bio, Inc., a clinical-stage biotechnology company focused on targeted cell therapies for autoimmune diseases, announced that updated clinical data on its investigational therapy, ...
The 2023 Fall Clinical Dermatology conference will take place in Las Vegas and be livestreamed from October 19 to 22; topics of interest to be covered include atopic dermatitis (AD), Janus kinase (JAK ...
Even with the recent awareness that clinical trials often lack the diversity that would make them representative, women and people of color remain underrepresented in studies. The work of bringing ...
Sanofi's amlitelimab has shown promise in the Phase III COAST 1 trial, but data from the COAST 2 study is yet to be announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results